Brief: Inventiva Announces Changes To The Clinical Development Of Lanifibranor, Including Plans For A New Phase III Trial In Patients With Nash And Compensated Cirrhosis
04/01/2023 21:01
Jan 4 (Reuters) - Inventiva SA IVAA.PA :
* INVENTIVA ANNOUNCES CHANGES TO THE CLINICAL DEVELOPMENT OF
LANIFIBRANOR, INCLUDING PLANS FOR A NEW PHASE III TRIAL IN
PATIENTS WITH NASH AND COMPENSATED CIRRHOSIS
Source text for Eikon: ID:nGNESjJKM
Further company coverage: IVAA.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inventiva SA
See all newsFrance's Inventiva H1 net loss narrows
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Inventiva Announces Last Patient Visit In Nativ3 Phase 3 Clinical Trial Of Lanifibranor In Mash
Brief: Inventiva Announces Comprehensive Capital Structure Optimization Including Debt And Equity Financing In Advance Of The Anticipated Phase 3 Readout
Brief: Inventiva Secures Up To €150 Mln Debt Financing, Extends Debt Maturity To 2030